SCHEMBL6665282

SCHEMBL6665282

O=S(=O)(Nc1ccc2c(ccn2-c2cccnc2)c1)c1cccc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KMT2A Q03164 3/20 0.44
BRD1 O95696 2/20 0.44
BRPF1 P55201 2/20 0.44
TSHR P16473 1/20 0.44
BRD4 O60885 1/20 0.44
BRD9 Q9H8M2 1/20 0.44
BRPF3 Q9ULD4 1/20 0.44
PTPN1 P18031 2/20 0.44
PTPN5 P54829 2/20 0.44
HSPD1 P10809 1/20 0.44
PTPN2 P17706 1/20 0.44
HSPE1 P61604 1/20 0.44
MEN1 O00255 1/20 0.44
AURKA O14965 1/20 0.43
KDR P35968 1/20 0.43
AURKB Q96GD4 1/20 0.43
PGR P06401 1/20 0.43
MAP2K4 P45985 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656125 0.89 MEN1 (0.57) LMNASMN1; SMN2KMT2ABRD1BRPF1
SCHEMBL6844273 0.88 BRD4 (0.57) LMNASMN1; SMN2KMT2ABRD1BRPF1
SCHEMBL6844486 0.88 KMT2A (0.47) LMNASMN1; SMN2KMT2ABRD1BRPF1
SCHEMBL6656751 0.84 ALPL (0.49) LMNAKMT2AMEN1
SCHEMBL6840912 0.83 POLB (0.54) LMNASMN1; SMN2KMT2ABRD1BRPF1
SCHEMBL6845454 0.82 KMT2A (0.51) SMN1; SMN2KMT2ABRD1BRPF1TSHR
SCHEMBL6840520 0.82 ALPL (0.46) LMNAKMT2ABRD1BRPF1BRD4
SCHEMBL6656738 0.81 ALPL (0.45) LMNAKMT2ABRD1BRPF1MEN1
SCHEMBL6658847 0.80 BRPF1 (0.60) BRD1BRPF1BRD4BRD9BRPF3
SCHEMBL6847813 0.80 KEAP1 (0.60) LMNASMN1; SMN2KMT2ABRD1BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed
US-20040224945-A1 Novel substituted pyrazole derivatives BAYER HEALTHCARE AG (DE) 2004-11-11 US disclosed
EP-1432698-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027094-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 LMNA 3128/4885SMN1; SMN2 4413/4885KMT2A 1387/4885
US-20040224945-A1 Novel substituted pyrazole derivatives CYP11B2, CYP11B1, ADRB3 LMNA 2016/4885SMN1; SMN2 4007/4885KMT2A 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.